Parkinson's Disease Foundation Announces $1 Million for Novel Studies Into Parkinson’s - Parkinson's Disease Foundation (PDF) - Jul 07 2011 (New York, NY) The Parkinson’s Disease Foundation (PDF) is pleased to announce awards totaling more than $1 million for 11 novel investigator-initiated research projects designed to understand the cause(s) of and find a cure for Parkinson’s disease. Investigator-driven projects are a core piece of PDF’s philosophy to empower the community – of scientists, clinicians, people with Parkinson’s and health care professionals – to find creative solutions benefitting the seven to 10 million people worldwide living with Parkinson’s.
The projects are funded through two key programs: the International Research Grants program and the Research Fellowships program, which both seek to encourage novel ideas by respectively funding “high-risk/high-reward” projects and supporting scientists in the early stages of their careers. For example, Parkinson’s research has typically focused on dopamine and its role in an area of the brain called the substantia nigra. Her fellow awardees, Sarah B.
A THIRD OF PEOPLE WITH PARKINSON'S DISEASE HAVE DYSPHAGIA. 14th July 2011 - New research Dysphagia [2011] 26 (1) : 92-96 (Walker RW, Dunn JR, Gray WK.) Complete abstract A third of people with Parkinson's Disease have been found to experience dysphagia. Dysphagia is difficulty with swallowing. This can cause eating and drinking problems, and more seriously causes choking, which can be fatal. For more information go to Dysphagia. The reason why dysphagia is so common in Parkinson's Disease is that the insufficient dopamine in Parkinson's Disease can affect all muscles, including those needed for swallowing, of which there are many. E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News, please merely e-mail mail@viartis.net with the message "subscribe".
DUAL LAYER L-DOPA CLINICAL TRIAL RESULTS. DRUGS CAUSING PARKINSON'S DISEASE. 17th June 2011 - New research Movement Disorders [2011] June 14 [Epub ahead of print] (Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL.) Complete abstract A study assessing over 20,000 adverse drug reactions has found those drugs that can cause or worsen Parkinson's Disease.
This is normally described as drug induced Parkinsonism. Among the suspect drugs, most involved central dopaminergic antagonists (49%), followed by antidepressants (8%), calcium channel blockers (5%), peripheral dopaminergic antagonists (5%), and H1 antihistamines (5%). Cases with lithium, valproic acid, amiodarone, anticholinesterases, or trimetazidine were also found.
Some problems occurred due to the interaction of other drugs. The majority (60%) of people affected were female. URINARY DYSFUNCTION IN PARKINSON'S DISEASE. 23rd June 2011 - New research Neurology, Neurosurgery and Psychiatry [2011] June 13 [Epub ahead of print] (Uchiyama T, Sakakibara R, Yamamoto T, Ito T, Yamaguchi C, Awa Y, Yanagisawa M, Higuchi Y, Sato Y, Ichikawa T, Yamanishi T, Hattori T, Kuwabara S.) Complete abstract Urinary dysfunction is common in Parkinson's Disease, but little was known about urinary dysfunction in early and untreated Parkinson's Disease. After excluding those with other conditions that might have influenced urinary function, patients were evaluated using a urinary questionnaire and urodynamic studies. Of urinary difficulty is detrusor underactivity. E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News, please merely e-mail mail@viartis.net with the message "subscribe".
RASAGILINE CLINICAL TRIAL RESULTS. 25th June 2011 - New research Lancet Neurology [2011] 10 (5) : 415-423 (O.Rascol, C.J. Fitzer-Attas, R.Hauser, J.JankovicJ, A.Lang, J.W.Langston, E. Melamed, W.Poewe, F.Stocchi, E.Tolosa, E.Eyal, Y.M.Weiss, C. W.Olanow) Complete abstract The ADAGIO study investigated whether Rasagiline has disease-modifying effects in Parkinson's Disease. Rasagiline is a MAO-B inhibitor, that is also known by the brand name Azilect. Initiation of Rasagiline was delayed for 36 weeks. E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News, please merely e-mail mail@viartis.net with the message "subscribe".
LOW RESOLUTION VERSION : There is a low resolution version of PARKINSON'S DISEASE NEWS INTENDED FOR THOSE PEOPLE THAT EITHER : use 800x600 resolution on their monitors, or have eyesight difficulties, or slow Internet speeds. DID GENERAL MACARTHUR HAVE PARKINSON'S DISEASE ? 12th May 2011 - New research Neurology [2011] 76 (19) : 1668-1672 (Bowen LN, Malaty IA, Rodriguez RL, Okun MS.) Complete abstract Historians have often claimed that General MacArthur had Parkinson Disease, and that his illness may have influenced his military judgment.
General MacArthur (1880-1964) was Chief of Staff of the U.S. Army and played a prominent role as a Field Marshall in World War 2. Researchers reviewed the literature, medical studies, images and videos concerning General MacArthur as well as his personal writings to determine the likelihood that he had Parkinson's Disease. E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News, please merely e-mail mail@viartis.net with the message "subscribe". RETINAL STEM CELLS FAIL TO RID PARKINSON'S DISEASE. 15th May 2011 - New research Lancet Neurology [2011] May 10 [Epub ahead of print] (Gross RE, Watts RL, Hauser RA, Bakay RA, Reichmann H, von Kummer R, Ondo WG, Reissig E, Eisner W, Steiner-Schulze H, Siedentop H, Fichte K, Hong W, Cornfeldt M, Beebe K, Sandbrink R) Complete abstract Human retinal pigment epithelial (RPE) cells in the eyes also produce L-dopa.
So their transplantation into the brain of people with Parkinson's Disease was considered to be able to improve the continuity of the administration of L-dopa better than the use of oral L-dopa. Researchers aimed to assess the safety, tolerability, and efficacy of transplantation of human retinal pigment epithelial cells into people with advanced Parkinson's Disease. Around 650,000 cells were injected in to the brain of each patient. Each person's symptoms were then assessed after a year. However, it was found that the treatment made no difference at all concerning their Parkinson's Disease symptoms. MISDIAGNOSIS IN PARKINSON'S DISEASE. 23rd May 2011 - New review Misdiagnosis in Parkinson's Disease is very common. Initial diagnoses of Parkinson's Disease made by general neurologists were only infrequently changed [reference 1], yet were incorrect in 24% to 35% of cases [reference 1] [reference 2].
This means that many people have been treated for Parkinson's Disease for the rest of their lives without ever having had Parkinson's Disease. In people taking Parkinson's Disease drugs, Parkinsonism was confirmed in only 74% of cases and only 53% of them had probable Parkinson's Disease. Patients did not benefit from Parkinson's Disease drugs [reference 2] [reference 3]. E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News, please merely e-mail mail@viartis.net with the message "subscribe".
THE WORST NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE. 27th February 2011 - New research Movement Disorders [2010] 25 (15) : 2493-2500 (Gallagher DA, Lees AJ, Schrag A.) Complete abstract Although muscular movement is the most characteristic symptom of Parkinson's Disease, non-motor symptoms (those that do not concern muscular movement) are increasingly recognised as neglected aspects of Parkinson's Disease. The most common non-motor symptom has been found to be urinary. In order of frequency the most common symptoms are : autonomic dysfunction, particularly urinary and gastrointestinal symptoms (84%), mood (74%), fatigue (74%), daytime somnolence (65%), pain (56%), nocturnal sleep problems (55%), and psychosis (55%). Motor fluctuations (57%) and dyskinesia (43%) were associated with worse quality of life. E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News, please merely e-mail mail@viartis.net with the message "subscribe".
THE PREVALENCE OF EYE DISORDERS IN PARKINSON'S DISEASE. 13th January 2011 - New research Klinica Oczna [2010] 112 (7-9) : 247-252 (Nowacka B, Lubinski W, Karczewicz D.) Complete abstract Based on the available medical literature, the authors described the most frequent ocular diseases (eye disorders) and symptoms, as well as bioelectrical dysfunction of the visual pathway in patients with Parkinson's Disease. The most frequent eye disorders in Parkinson's Disease were found to be dry eye syndrome and glaucoma. In Dry Eye Syndrome, the lack of moistness in the eyes can cause eyes to become dry, itchy, red, gritty, or blurred. For more information go to Dry Eye Syndrome. E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News, please merely e-mail mail@viartis.net with the message "subscribe".
TOXIC CAUSES OF PARKINSON'S DISEASE. 8th December 2010 - New review There are now fourteen known toxic causes of Parkinson's Disease : pesticides (Paraquat, Rotenone, Maneb), solvents (Trichloroethylene, Toluene, N-Hexane, Carbon disulfide), MPTP, Mercury, Manganese, Copper, Carbon monoxide, Lead, Cyanide. Although Agent Orange is widely claimed to be a toxic cause of Parkinson's Disease, not even one study in the entire medical literature has ever shown that to be true. Toxicity has the potential to be the sole cause of Parkinson's Disease.
To very varying extents, toxicity can also be a partial cause of Parkinson's Disease. The prevalence of Parkinson's Disease that is due to toxicity is not known. In order to cause Parkinson's Disease, the level of toxic exposure usually has to be either acute or chronic. Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease.
ROTIGOTINE (NEUPRO) CLINICAL TRIAL RESULTS. 21st February 2011 - New research Movement Disorders [2011] 26 (1) : 90-99 (Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR) Complete abstract People with Parkinson's Disease who had unsatisfactory early-morning motor symptom control were given either rotigotine (2mg-16mg rotigotine every 24 hours) or a placebo.
Neupro® (Rotigotine Transdermal System) is a dopamine agonist that is applied to the skin in order to continuously deliver rotigotine over a 24-hour period. For more information go to Neupro. In April 2008, Neupro was withdrawn from use in the U.S.A. because specific batches of Neupro had deviated from their specification. INTRANASAL STEM CELLS FOR PARKINSON'S DISEASE. 9th February 2011 - New research Rejuvenation Research [2011] February [ahead of print] (Lusine Danielyan, Richard Schäfer, Andreas von Ameln-Mayerhofer, Felix Bernhard, Stephan Verleysdonk, Marine Buadze, Ali Lourhmati, Tim Klopfer, Felix Schaumann, Barbara Schmid, Christoph Koehle, Barbara Proksch, Robert Weissert, Holger M. Reichardt, Jens van den Brandt, Gayane H.
Buniatian, Matthias Schwab, Christoph H. Gleiter, William H. Frey) Complete study Stem cells have been delivered intranasally (via the nose), as a means of trying to treat Parkinson's Disease. Intranasal administration of stem cells to the brain is a proposed alternative to the current surgical procedures, which place stem cells directly in to the brain. Delivered to the brain. E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News, please merely e-mail mail@viartis.net with the message "subscribe".
THE RISK OF COMPULSIONS IN PARKINSON'S DISEASE. 18th February 2011 - New research Parkinsonism Related Disorders [2011] Feb 8 [Epub ahead of print] (Hassan A, Bower JH, Kumar N, Matsumoto JY, Fealey RD, Josephs KA, Ahlskog JE) Complete abstract Dopamine agonist treatment of Parkinson's Disease carries a greatly increased risk of compulsive behaviour. Compulsive behaviour provoked by dopamine agonists often goes undetected in clinical series, especially if they are not specifically enquired about. Of those people with Parkinson's Disease taking dopamine agonists 22% experienced compulsive behaviour, and 16% were pathologic. However, when the analysis was restricted to patients taking dopamine agonist doses that were at least minimally therapeutic, pathological behaviours were documented in 24% of people.
LOW RESOLUTION VERSION : There is a low resolution version of PARKINSON'S DISEASE NEWS INTENDED FOR THOSE PEOPLE THAT EITHER : use 800x600 resolution on their monitors, or have eyesight difficulties, or slow Internet speeds.